Pathfinder
Editor, Senior Moderator
Israeli oral COVID-19 vaccine en route to clinical trials
...
By MAAYAN JAFFE-HOFFMAN JUNE 11, 2021 06:26
...
The company is calling their vaccine MigVax-101. Unlike the Pfizer or Moderna vaccines that use messenger RNA, this is an oral subunit vaccine, meaning the vaccine presents the coronavirus antigen to the immune system without introducing pathogen particles, whole or otherwise.
In the preclinical trial, the company administered the vaccine in a boost format to the rats following a double injection of the coronavirus spike (S1) protein. The results showed that using MigVax as a booster elicited markedly higher neutralizing antibody titers than rats receiving an oral placebo booster, a release explained. In addition, it elicited more effective neutralizing antibodies than a third S1 booster injection.
“They are looking to use this as a booster for those who took the Chinese vaccine, AstraZeneca or Moderna or Pfizer,” Dr. Morris Laster, who is responsible for medical technology investments for OurCrowd told The Jerusalem Post. OurCrowd led MigVax’s first investment round.
According to Laster, the vaccine has several advantages, including that because it is an oral vaccine it would not require administration by a medical professional. Also, it utilizes more than one kind of protein, which could make it more effective against variants. The vaccine does not require freezing conditions like the mRNA vaccines so it could be easier to store and distribute.
Finally, because it does not inject people with genetic or viral material, Laster believes that more people will be prone to taking it.
...
https://www.jpost.com/health-scienc...ovid-19-vaccine-works-as-booster-study-670679
...
By MAAYAN JAFFE-HOFFMAN JUNE 11, 2021 06:26
...
The company is calling their vaccine MigVax-101. Unlike the Pfizer or Moderna vaccines that use messenger RNA, this is an oral subunit vaccine, meaning the vaccine presents the coronavirus antigen to the immune system without introducing pathogen particles, whole or otherwise.
In the preclinical trial, the company administered the vaccine in a boost format to the rats following a double injection of the coronavirus spike (S1) protein. The results showed that using MigVax as a booster elicited markedly higher neutralizing antibody titers than rats receiving an oral placebo booster, a release explained. In addition, it elicited more effective neutralizing antibodies than a third S1 booster injection.
“They are looking to use this as a booster for those who took the Chinese vaccine, AstraZeneca or Moderna or Pfizer,” Dr. Morris Laster, who is responsible for medical technology investments for OurCrowd told The Jerusalem Post. OurCrowd led MigVax’s first investment round.
According to Laster, the vaccine has several advantages, including that because it is an oral vaccine it would not require administration by a medical professional. Also, it utilizes more than one kind of protein, which could make it more effective against variants. The vaccine does not require freezing conditions like the mRNA vaccines so it could be easier to store and distribute.
Finally, because it does not inject people with genetic or viral material, Laster believes that more people will be prone to taking it.
...
https://www.jpost.com/health-scienc...ovid-19-vaccine-works-as-booster-study-670679
